Nektar Therapeutics (NKTR) News
Filter NKTR News Items
NKTR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NKTR News Highlights
- NKTR's 30 day story count now stands at 3.
- Over the past 4 days, the trend for NKTR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about NKTR are JAZZ, ASH and BL.
Latest NKTR News From Around the Web
Below are the latest news stories about NEKTAR THERAPEUTICS that investors may wish to consider to help them evaluate NKTR as an investment opportunity.
Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual MeetingNektar Therapeutics (NASDAQ:NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College presented a poster highlighting new preclinical data on NKTR-255 at the 65th American Society of Hematology (ASH) Annual Meeting demonstrating that NKTR-255 significantly enhanced the cytotoxicity of expanded Natural Killer (NK) cells when combined with obinutuzumab against rituximab-resistant BL cells and significantly improved the survival of mice xenografted with Raji-4RH compa |
Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report?Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue?Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call TranscriptNektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript November 7, 2023 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.24 EPS, expectations were $-0.18. Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that today’s conference is […] |
Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 LossNektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line. |
Nektar Therapeutics Reports Third Quarter 2023 Financial ResultsNektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2023. |
Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial MarketsNektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. |
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
12 Best Penny Stocks to Buy Under $1In this article, we will take a look at the 12 best penny stocks to buy under $1. To see more such companies, go directly to 5 Best Penny Stocks to Buy Under $1. Investors are optimistic as we move into the third quarter earnings season. Hopes in the Wall Street are growing that we […] |
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV CongressNektar Therapeutics (NASDAQ:NKTR) today announced new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, in patients with atopic dermatitis (AD) at the 2023 European Academy of Dermatology and Venereology (EADV) Congress. These data were presented by Dr. Jonathan Silverberg, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences and Director of Clinical Research and Contact Dermatitis in a late-breaking o |